Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone
hydrochloride extended release tablets (Sandoz) with Opana extended release oxymorphone
hydrochloride tablets.